Back


10/06/2017
New analysis shows Soliqua® 100/33 lowered HbA1c by more than 2% in patients with screening levels greater than 9%
Zealand Pharma’s ("Zealand") partner Sanofi announced today that Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100 units/ml and 33 mcg/ml lowered mean blood sugar levels (HbA1c) by 1.09-2.41% after 30 weeks in adults with type 2 diabetes previously treated with 15-40 units of basal insulin daily. [...]

Download the pdf file





X

X